Bladder cancer is a global health issue with sex differences in incidence and prognosis.
Bladder cancer has distinct molecular subtypes with multiple pathogenic pathways …

Context Bladder cancer (BC) is common worldwide and poses a significant public health
challenge. External risk factors and the wider exposome (totality of exposure from external …

Bladder cancer is one of the most common malignancies in the world. Cisplatin is one of the
most potent and widely used anticancer drugs and has been employed in several …

Background Previous randomised controlled trials comparing bladder preservation with
radical cystectomy for muscle-invasive bladder cancer closed due to insufficient accrual …

Bladder cancer (BC) is the 11th most popular cancer in females and 4th in males. A lot of
efforts have been exerted to improve BC patients' care. Besides, new approaches have …

Cancer is a complex disease that causes abnormal genetic changes and unchecked cellular
growth. It also causes a disruption in the normal regulatory processes that leads to the …

Currently, certain cancer patients exhibit resistance to radiotherapy due to reduced DNA
damage under hypoxic conditions and acquired immune tolerance triggered by transforming …

Background We predicted cancer mortality figures for 2024 for the European Union (EU), its
five most populous countries, and the UK. We focused on mortality from colorectal cancer …

Both cisplatin‐based chemotherapy and immune checkpoint blockers (ICBs)‐based
immunotherapy are the first‐line treatments for patients with advanced bladder cancer …

Muscle-invasive urothelial cancer (MUC), characterized by high aggressiveness and
significant heterogeneity, is currently lacking highly precise individualized treatment options …